Ferric citrate: a novel phosphate-binding agent

被引：0

作者：

Umanath, Kausik ^{[1
]}

Niecestro, Robert

Lewis, Julia B. ^{[2
]}

Dwyer, Jamie P. ^{[2
]}

机构：

[1] Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA

[2] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Nashville, TN USA

来源：

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | 2013年 / 8卷 / 01期

关键词：

CKD-MBD; ESRD; iron metabolism; metabolic acidosis; phosphate binder;

D O I：

10.1586/EEM.12.66

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ferric citrate (KRX-0502; Keryx Biopharmaceuticals, Inc., NY, USA) is a novel phosphate-binding agent presently in Phase III clinical development. Ferric citrate dissociates in the bowel lumen releasing the ferric ion to precipitate with dietary phosphorus, which is then excreted in the stool. Studies to date have shown the agent to be efficacious and safe with only mild gastrointestinal side effects. Absorption of either component of the agent (ferric iron or citrate) has the potential to be of benefit for patients with end-stage renal disease. An ongoing Phase III trial is confirming the safety and efficacy of ferric citrate as a phosphate binder in dialysis patients.

引用

页码：13 / 19

页数：7

共 50 条

[1] Comparative analysis of the phosphate-binding effects of sucroferric oxyhydroxide, ferric citrate, and lanthanum carbonate
Ishii T.
Nakajima Y.
Oyama K.
Renal Replacement Therapy, 3 (1)
[2] Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer
Nakaki, Junko
Yamaguchi, Shinichi
Torii, Yuichi
Inoue, Atsushi
Minakami, Satoshi
Kanno, Takami
Murakami, Masanori
Tsuzuki, Masahiro
Mochizuki, Hidenori
Suyama, Kazuharu
Miyamoto, Mitsuko
EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 714 (1-3) : 312 - 317
[3] Phosphate-binding capacity of ferrihydrite versus calcium acetate in rats
Weaver, CM
Schulze, DG
Peck, LW
Magnusen, HM
Martin, BR
Gruenhagen, SE
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (02) : 324 - 327
[4] Safety and Phosphate-Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers
Pergola, Pablo E.
Joy, Melanie S.
Garsd, Armando
Hasal, Steve J.
Khare, Atul
Reddy, Guru
Gupta, Pramod
Finn, William F.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (01):
[5] Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound
Melissa A. Plone
John S. Petersen
David P. Rosenbaum
Steven K. Burke
Clinical Pharmacokinetics, 2002, 41 : 517 - 523
[6] Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients
Hanudel, Mark R.
Laster, Marciana
Ramos, Georgina
Gales, Barbara
Salusky, Isidro B.
PEDIATRIC NEPHROLOGY, 2018, 33 (11) : 2137 - 2142
[7] Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients
Mark R. Hanudel
Marciana Laster
Georgina Ramos
Barbara Gales
Isidro B. Salusky
Pediatric Nephrology, 2018, 33 : 2137 - 2142
[8] Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials
Palmer, Suetonia C.
Gardner, Sharon
Tonelli, Marcello
Mavridis, Dimitris
Johnson, David W.
Craig, Jonathan C.
French, Richard
Ruospo, Marinella
Strippoli, Giovanni F. M.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (05) : 691 - 702
[9] Interaction and mechanisms in the phosphate-binding of iron(oxyhydr) oxide core-shell nanoparticles
Spicher, Magdalena Teresa
Schwaminger, Sebastian Patrick
von der Haar-Leistl, Daniela
Reindl, Marco
Wagner, Friedrich Ernst
Berensmeier, Sonja
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2023, 634 : 418 - 430
[10] Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs
Rodby, Roger
Umanath, Kausik
Niecestro, Robert
Jackson, James H.
Sika, Mohammed
Lewis, Julia B.
Dwyer, Jamie P.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (03) : 545 - 550

← 1 2 3 4 5 →